modelLevocabastine
Extends from Pharmacolibrary.Drugs.ATC.S.S01GX02.
Information
| name: | Levocabastine | |
| ATC code: | S01GX02 | route: | ocular |
| compartments: | 1 | |
| dosage: | 0.54 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 0.05 | L/h/kg |
| other parameters in model implementation | ||
Levocabastine is a selective second-generation histamine H1 receptor antagonist used primarily as an ophthalmic solution for symptomatic relief of allergic conjunctivitis. It is administered topically and has minimal systemic effects due to low absorption. Levocabastine is approved in some countries for ocular and intranasal use for allergic symptoms.
Pharmacokinetics
Pharmacokinetics in healthy adult volunteers after ocular administration.
References
Heykants, J, et al., & Woestenborghs, R (1995). The pharmacokinetic properties of topical levocabastine. A review. Clinical pharmacokinetics 29(4) 221–230. DOI:10.2165/00003088-199529040-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8549024
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)